Eric Lefkofsky is an entrepreneur as well as a liberal person who has carried out many charitable activities on behalf of the community in Chicago. He has co-founded and successfully headed several companies including Lightbank, Groupon, Echo Global Logistics, Media Ocean as well as InnerWorkings. Most of his endeavors seek to embrace and implement the latest technology to bring out the best.
Most of his humanitarian works get done through the charitable trust he and his wife Liz started in the year 2006, Lefkofskys’ Family Foundation. Through it, they have been able to support and improve the quality of life of the people in Chicago by promoting education, health, art and culture, technology as well as human rights protection. One of the greatest start-up project that Lefkofsky has invested in and which brings out his philanthropic being and love for other was through Tempus.
Eric Lefkofsky is a co-founder and the CEO of the technology company, Tempus which was created with the aim of battling cancer. Use of latest and advanced technology is what makes the mission of Tempus to be achieved because it helps physicians to provide personalized care to cancer patients. They do this through the artificial intelligence provided by the machine learning platforms. Through the services offered by the company the physicians gets the required and accurate data about a patient so as to make real-time decisions based on the data received. Tempus aims at providing a massive database where the doctors can be referring to before treating other patients.
For data analytics, Tempus uses deep machine learning as well as genomic sequencing to as to get the real information on every patient’s tumor. It also provides the doctors with phenotypic, molecular and therapeutic intuitions within the clinical setting so that they can deliver the best standard of care to the patients. Tempus’ analytic platform enables all the physicians to intensely understand the patient’s cancer by collecting and analyzing massive genomic data through the use of proprietary algorithms. Through this analysis and the combination of other patients with same molecular profiles, the doctors can give a personalized treatment such as therapies that are approved by FDA.
The results gotten from the dynamic analysis can then be validated through the use of Vitro and in Vivo Patient-derivative biological models before they are clinically deployed. Tempus applies independent as well collaborative testing with doctors and researchers so as to develop an automated cell-culture technology that helps build a report about the patient’s cancer condition. The report also details the information to be used by the physician to develop a personalized care plan and treatment for the patient.
Tempus might be the long awaited solution for cancer treatment and through the technology applied the cancer patients might as well be helped to live longer. Lefkofsky believes in the risk that will make a difference to the lives of the victims of the deadly disease, cancer.